Prognostic Factors in Pleural Mesothelioma Patients Receiving First-Line Chemotherapy: Establishing the PLECH...

Area of Science:

• Oncology
• Medical Statistics
• Cancer Prognostics

Background:

• Pleural mesothelioma (PM) is a rare, aggressive cancer requiring accurate prognostication.
• Existing prognostic scores (EORTC, CALGB) have limitations in reflecting modern treatments and diverse patient populations.
• Novel scores often rely on biomarkers with limited availability and validation.

Purpose of the Study:

• To develop a novel, effective prognostic score for unresectable pleural mesothelioma (PM).
• To utilize easily accessible baseline clinical data for score development.
• To compare the predictive performance of the new score against established prognostic tools.

Main Methods:

• Retrospective cohort study of 262 unresectable PM patients receiving first-line chemotherapy (2010-2023) at two Mexican cancer centers.
• Analysis of baseline variables for association with overall survival (OS) and progression-free survival (PFS).
• Development of the PLECH score and comparison with CALGB and EORTC scores using ROC curves and Kaplan-Meier analysis.

Main Results:

• The 0-7 point PLECH score incorporates Platelet count, LDH, ECOG performance status, Chest pain, and Histology.
• The PLECH score demonstrated superior 1-year OS prediction (AUC 0.70) compared to CALGB (0.60) and EORTC (0.57).
• Higher PLECH scores (≥3) significantly correlated with worse OS (12.3 vs. 20.1 months) and PFS (6.4 vs. 11.3 months).

Conclusions:

• The PLECH score is a simple, effective prognostic tool for pleural mesothelioma patients, validated in a Latin-American cohort.
• It outperforms traditional prognostic scores like CALGB and EORTC.
• The PLECH score aids in identifying high-risk patients who may benefit from alternative therapeutic strategies.